文献速递免疫规划传染病防控与疫情报告

2023-2024年更新版(单价XBB.1.5)COVID-19疫苗对免疫功能正常成人COVID-19相关急诊和紧急护理就诊及住院的 interim 有效性——VISION和IVY网络,2023年9月至2024年1月

Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2024-02-29

利用美国CDC两个疫苗有效性网络数据,采用检测阴性病例对照设计,评估2023-2024年更新版COVID-19疫苗对18岁及以上免疫功能正常成人COVID-19相关急诊/紧急护理就诊和住院的有效性。结果显示,接种更新剂量后7-59天对急诊/紧急护理就诊的有效性为51%,60-119天为39%;对住院的有效性分别为52%和43%。结果支持CDC关于2023-2024年更新版COVID-19疫苗接种的建议。

要点

  • 更新版疫苗对COVID-19相关急诊/紧急护理就诊的有效性在接种后7-59天为51%,60-119天为39%。
  • 对COVID-19相关住院的有效性在接种后7-59天为52%,60-119天为43%。
  • 所有6月龄及以上人群应接种2023-2024年更新版COVID-19疫苗。

核心结论

  • 更新版COVID-19疫苗为免疫功能正常成人提供了针对COVID-19相关急诊/紧急护理就诊和住院的额外保护。
  • 这些结果支持CDC关于2023-2024年更新版COVID-19疫苗接种的建议。

研究设计与样本

  • 采用检测阴性病例对照设计,数据来自美国CDC的两个疫苗有效性网络(VISION和IVY网络)。
  • 分析对象为2023年9月至2024年1月期间18岁及以上免疫功能正常成人。

主要发现

  • 接种更新剂量后7-59天,对COVID-19相关急诊/紧急护理就诊的有效性为51%(95% CI = 47%-54%)。
  • 接种更新剂量后60-119天,对COVID-19相关急诊/紧急护理就诊的有效性为39%(95% CI = 33%-45%)。
  • 两个CDC疫苗有效性网络估计的针对COVID-19相关住院的有效性分别为52%(95% CI = 47%-57%)和43%(95% CI = 27%-56%),接种更新剂量后的中位间隔分别为42天和47天。

关键数值与推荐

  • 2023年9月,CDC免疫实践咨询委员会推荐所有6月龄及以上人群接种2023-2024年更新版(单价XBB.1.5)COVID-19疫苗以预防COVID-19包括重症。
  • 所有6月龄及以上人群应接种2023-2024年更新版COVID-19疫苗。

临床怎么用

  • 研究结果支持CDC关于2023-2024年更新版COVID-19疫苗接种的建议。
  • 所有6月龄及以上人群应接种2023-2024年更新版COVID-19疫苗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. However, few estimates of updated vaccine effectiveness (VE) against medically attended illness are available. This analysis evaluated VE of an updated COVID-19 vaccine dose against COVID-19-associated emergency department (ED) or urgent care (UC) encounters and hospitalization among immunocompetent adults aged ≥18 years during September 2023-January 2024 using a test-negative, case-control design with data from two CDC VE networks. VE against COVID-19-associated ED/UC encounters was 51% (95% CI = 47%-54%) during the first 7-59 days after an updated dose and 39% (95% CI = 33%-45%) during the 60-119 days after an updated dose. VE estimates against COVID-19-associated hospitalization from two CDC VE networks were 52% (95% CI = 47%-57%) and 43% (95% CI = 27%-56%), with a median interval from updated dose of 42 and 47 days, respectively. Updated COVID-19 vaccine provided increased protection against COVID-19-associated ED/UC encounters and hospitalization among immunocompetent adults. These results support CDC recommendations for updated 2023-2024 COVID-19 vaccination. All persons aged ≥6 months should receive updated 2023-2024 COVID-19 vaccine.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. DeCuir J, Payne AB, Self WH, et al. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38421945. doi:10.15585/mmwr.mm7308a5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。